Trial Profile
A Comparative Effectiveness Study of Intravitreal Aflibercept, Bevacizumab and Ranibizumab for Diabetic Macular Edema
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 02 Sep 2021
Price :
$35
*
At a glance
- Drugs Aflibercept (Primary) ; Bevacizumab (Primary) ; Ranibizumab
- Indications Diabetic macular oedema
- Focus Therapeutic Use
- Acronyms Protocol T
- 01 Aug 2021 Results of post-hoc analysis (n=360) assessing the risk factors for fellow eye treatment of diabetic retinopathy with Vascular Endothelial Growth Factor (VEGF) injections during the Diabetic Retinopathy Clinical Research Network (DRCR.Net) Protocol T trial, published in the Graefes Archive for Clinical and Experimental Ophthalmology.
- 06 Nov 2019 Results assessing clinical and economic consequences of an extension of the loading dose of anti-VEGF treatments (at 3 and 6 months) in DME patients were presented at the 22nd Annual European Congress of the International Society for Pharmacoeconomics and Outcomes Research
- 20 Sep 2019 Status changed from active, no longer recruiting to completed.